---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-001559"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2021-08-25T23:59:59+00:00"
generated_at: "2026-06-29T07:53:23.182644+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences appoints Nancy Whiting to board of directors

## Summary
- Nancy Whiting, Pharm.D., appointed as Class II director effective August 24, 2021.
- She receives $40,000 annual cash retainer plus $5,000 for compensation committee service.
- Dr. Whiting brings over 17 years of biotech experience, most recently as EVP at Seagen Inc.
- Her oncology drug development expertise aligns with Caribou's pipeline of allogeneic cell therapies.

## SEC filing metadata
- accession: 0000950170-21-001559
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2021-08-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000095017021001559/0000950170-21-001559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000095017021001559/crbu-20210824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-001559
- JSON: https://secwatch.observer/filing/0000950170-21-001559.json
- Plain text: https://secwatch.observer/filing/0000950170-21-001559.txt

## Key facts
- Executive change
  Nancy C. Whiting was appointed as Director at Caribou Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: unanimously agreed to extend an offer to Nancy C. Whiting, Pharm. D. to serve as a Class II director of the Company, which offer Dr. Whiting accepted on August 24, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000095017021001559/0000950170-21-001559-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.